Antibody therapy in renal cell carcinoma

The treatment of metastasized renal cell carcinoma (RCC) still represents a formidable challenge, despite the development of small molecule, tyrosine kinase inhibitors (TKI) that have made a major impact on the disease. Although the percentage of patients achieving a partial response or stabilizatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Oosterwijk, Egbert, Boerman, Otto C., Oyen, Wim J. C., Old, Lloyd J., Mulders, Peter F. A.
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2008
Materias:
Topic Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2295251/
https://www.ncbi.nlm.nih.gov/pubmed/18239922
http://dx.doi.org/10.1007/s00345-008-0236-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2295251/
https://www.ncbi.nlm.nih.gov/pubmed/18239922
http://dx.doi.org/10.1007/s00345-008-0236-5

Ejemplares similares